Loading…

Discovery of new Mycobacterium tuberculosis proteasome inhibitors using a knowledge-based computational screening approach

Mycobacterium tuberculosis bacteria cause deadly infections in patients [Corrected]. The rise of multidrug resistance associated with tuberculosis further makes the situation worse in treating the disease. M. tuberculosis proteasome is necessary for the pathogenesis of the bacterium validated as an...

Full description

Saved in:
Bibliographic Details
Published in:Molecular diversity 2015-11, Vol.19 (4), p.1003-1019
Main Authors: Mehra, Rukmankesh, Chib, Reena, Munagala, Gurunadham, Yempalla, Kushalava Reddy, Khan, Inshad Ali, Singh, Parvinder Pal, Khan, Farrah Gul, Nargotra, Amit
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 1019
container_issue 4
container_start_page 1003
container_title Molecular diversity
container_volume 19
creator Mehra, Rukmankesh
Chib, Reena
Munagala, Gurunadham
Yempalla, Kushalava Reddy
Khan, Inshad Ali
Singh, Parvinder Pal
Khan, Farrah Gul
Nargotra, Amit
description Mycobacterium tuberculosis bacteria cause deadly infections in patients [Corrected]. The rise of multidrug resistance associated with tuberculosis further makes the situation worse in treating the disease. M. tuberculosis proteasome is necessary for the pathogenesis of the bacterium validated as an anti-tubercular target, thus making it an attractive enzyme for designing Mtb inhibitors. In this study, a computational screening approach was applied to identify new proteasome inhibitor candidates from a library of 50,000 compounds. This chemical library was procured from the ChemBridge (20,000 compounds) and the ChemDiv (30,000 compounds) databases. After a detailed analysis of the computational screening results, 50 in silico hits were retrieved and tested in vitro finding 15 compounds with IC₅₀ values ranging from 35.32 to 64.15 μM on lysate. A structural analysis of these hits revealed that 14 of these compounds probably have non-covalent mode of binding to the target and have not reported for anti-tubercular or anti-proteasome activity. The binding interactions of all the 14 protein-inhibitor complexes were analyzed using molecular docking studies. Further, molecular dynamics simulations of the protein in complex with the two most promising hits were carried out so as to identify the key interactions and validate the structural stability.
doi_str_mv 10.1007/s11030-015-9624-0
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1718906971</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1718906971</sourcerecordid><originalsourceid>FETCH-LOGICAL-p126t-fa20f170deda01c0c250bdb970266083069dc215dd674dd9e99407b8bf9176f53</originalsourceid><addsrcrecordid>eNo1kMtOwzAURC0kREvhA9ggL9kErp3GrpeoPKUiNiCxi_y4aQ1JHOyEqnw9EZTVbI7OaIaQMwaXDEBeJcYghwxYkSnB5xkckCkrZJ4VwN4m5Dild4CRZPkRmXDBcw5cTcn3jU82fGHc0VDRFrf0aWeD0bbH6IeG9oPBaIc6JJ9oF0OPOoUGqW833vg-xESH5Ns11fSjDdsa3RozoxM6akPTDb3ufWh1TZONiO0v2Y0ebTcn5LDSdcLTfc7I693ty_IhWz3fPy6vV1nHuOizSnOomASHTgOzYHkBxhklgQsBixyEcpazwjkh584pVGoO0ixMpZgUVZHPyMWfd6z9HDD1ZTNuxrrWLYYhlUyyhRotko3o-R4dTIOu7KJvdNyV_3_lP7U7bmE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1718906971</pqid></control><display><type>article</type><title>Discovery of new Mycobacterium tuberculosis proteasome inhibitors using a knowledge-based computational screening approach</title><source>Springer Nature</source><creator>Mehra, Rukmankesh ; Chib, Reena ; Munagala, Gurunadham ; Yempalla, Kushalava Reddy ; Khan, Inshad Ali ; Singh, Parvinder Pal ; Khan, Farrah Gul ; Nargotra, Amit</creator><creatorcontrib>Mehra, Rukmankesh ; Chib, Reena ; Munagala, Gurunadham ; Yempalla, Kushalava Reddy ; Khan, Inshad Ali ; Singh, Parvinder Pal ; Khan, Farrah Gul ; Nargotra, Amit</creatorcontrib><description>Mycobacterium tuberculosis bacteria cause deadly infections in patients [Corrected]. The rise of multidrug resistance associated with tuberculosis further makes the situation worse in treating the disease. M. tuberculosis proteasome is necessary for the pathogenesis of the bacterium validated as an anti-tubercular target, thus making it an attractive enzyme for designing Mtb inhibitors. In this study, a computational screening approach was applied to identify new proteasome inhibitor candidates from a library of 50,000 compounds. This chemical library was procured from the ChemBridge (20,000 compounds) and the ChemDiv (30,000 compounds) databases. After a detailed analysis of the computational screening results, 50 in silico hits were retrieved and tested in vitro finding 15 compounds with IC₅₀ values ranging from 35.32 to 64.15 μM on lysate. A structural analysis of these hits revealed that 14 of these compounds probably have non-covalent mode of binding to the target and have not reported for anti-tubercular or anti-proteasome activity. The binding interactions of all the 14 protein-inhibitor complexes were analyzed using molecular docking studies. Further, molecular dynamics simulations of the protein in complex with the two most promising hits were carried out so as to identify the key interactions and validate the structural stability.</description><identifier>EISSN: 1573-501X</identifier><identifier>DOI: 10.1007/s11030-015-9624-0</identifier><identifier>PMID: 26232029</identifier><language>eng</language><publisher>Netherlands</publisher><subject>Antitubercular Agents - chemistry ; Antitubercular Agents - pharmacology ; Computational Biology - methods ; High-Throughput Screening Assays - methods ; Humans ; Molecular Docking Simulation ; Molecular Dynamics Simulation ; Mycobacterium tuberculosis - drug effects ; Mycobacterium tuberculosis - enzymology ; Proteasome Inhibitors - chemistry ; Proteasome Inhibitors - pharmacology ; Protein Binding ; Quantitative Structure-Activity Relationship ; Small Molecule Libraries - chemistry ; Small Molecule Libraries - pharmacology</subject><ispartof>Molecular diversity, 2015-11, Vol.19 (4), p.1003-1019</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26232029$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mehra, Rukmankesh</creatorcontrib><creatorcontrib>Chib, Reena</creatorcontrib><creatorcontrib>Munagala, Gurunadham</creatorcontrib><creatorcontrib>Yempalla, Kushalava Reddy</creatorcontrib><creatorcontrib>Khan, Inshad Ali</creatorcontrib><creatorcontrib>Singh, Parvinder Pal</creatorcontrib><creatorcontrib>Khan, Farrah Gul</creatorcontrib><creatorcontrib>Nargotra, Amit</creatorcontrib><title>Discovery of new Mycobacterium tuberculosis proteasome inhibitors using a knowledge-based computational screening approach</title><title>Molecular diversity</title><addtitle>Mol Divers</addtitle><description>Mycobacterium tuberculosis bacteria cause deadly infections in patients [Corrected]. The rise of multidrug resistance associated with tuberculosis further makes the situation worse in treating the disease. M. tuberculosis proteasome is necessary for the pathogenesis of the bacterium validated as an anti-tubercular target, thus making it an attractive enzyme for designing Mtb inhibitors. In this study, a computational screening approach was applied to identify new proteasome inhibitor candidates from a library of 50,000 compounds. This chemical library was procured from the ChemBridge (20,000 compounds) and the ChemDiv (30,000 compounds) databases. After a detailed analysis of the computational screening results, 50 in silico hits were retrieved and tested in vitro finding 15 compounds with IC₅₀ values ranging from 35.32 to 64.15 μM on lysate. A structural analysis of these hits revealed that 14 of these compounds probably have non-covalent mode of binding to the target and have not reported for anti-tubercular or anti-proteasome activity. The binding interactions of all the 14 protein-inhibitor complexes were analyzed using molecular docking studies. Further, molecular dynamics simulations of the protein in complex with the two most promising hits were carried out so as to identify the key interactions and validate the structural stability.</description><subject>Antitubercular Agents - chemistry</subject><subject>Antitubercular Agents - pharmacology</subject><subject>Computational Biology - methods</subject><subject>High-Throughput Screening Assays - methods</subject><subject>Humans</subject><subject>Molecular Docking Simulation</subject><subject>Molecular Dynamics Simulation</subject><subject>Mycobacterium tuberculosis - drug effects</subject><subject>Mycobacterium tuberculosis - enzymology</subject><subject>Proteasome Inhibitors - chemistry</subject><subject>Proteasome Inhibitors - pharmacology</subject><subject>Protein Binding</subject><subject>Quantitative Structure-Activity Relationship</subject><subject>Small Molecule Libraries - chemistry</subject><subject>Small Molecule Libraries - pharmacology</subject><issn>1573-501X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNo1kMtOwzAURC0kREvhA9ggL9kErp3GrpeoPKUiNiCxi_y4aQ1JHOyEqnw9EZTVbI7OaIaQMwaXDEBeJcYghwxYkSnB5xkckCkrZJ4VwN4m5Dild4CRZPkRmXDBcw5cTcn3jU82fGHc0VDRFrf0aWeD0bbH6IeG9oPBaIc6JJ9oF0OPOoUGqW833vg-xESH5Ns11fSjDdsa3RozoxM6akPTDb3ufWh1TZONiO0v2Y0ebTcn5LDSdcLTfc7I693ty_IhWz3fPy6vV1nHuOizSnOomASHTgOzYHkBxhklgQsBixyEcpazwjkh584pVGoO0ixMpZgUVZHPyMWfd6z9HDD1ZTNuxrrWLYYhlUyyhRotko3o-R4dTIOu7KJvdNyV_3_lP7U7bmE</recordid><startdate>201511</startdate><enddate>201511</enddate><creator>Mehra, Rukmankesh</creator><creator>Chib, Reena</creator><creator>Munagala, Gurunadham</creator><creator>Yempalla, Kushalava Reddy</creator><creator>Khan, Inshad Ali</creator><creator>Singh, Parvinder Pal</creator><creator>Khan, Farrah Gul</creator><creator>Nargotra, Amit</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201511</creationdate><title>Discovery of new Mycobacterium tuberculosis proteasome inhibitors using a knowledge-based computational screening approach</title><author>Mehra, Rukmankesh ; Chib, Reena ; Munagala, Gurunadham ; Yempalla, Kushalava Reddy ; Khan, Inshad Ali ; Singh, Parvinder Pal ; Khan, Farrah Gul ; Nargotra, Amit</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p126t-fa20f170deda01c0c250bdb970266083069dc215dd674dd9e99407b8bf9176f53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Antitubercular Agents - chemistry</topic><topic>Antitubercular Agents - pharmacology</topic><topic>Computational Biology - methods</topic><topic>High-Throughput Screening Assays - methods</topic><topic>Humans</topic><topic>Molecular Docking Simulation</topic><topic>Molecular Dynamics Simulation</topic><topic>Mycobacterium tuberculosis - drug effects</topic><topic>Mycobacterium tuberculosis - enzymology</topic><topic>Proteasome Inhibitors - chemistry</topic><topic>Proteasome Inhibitors - pharmacology</topic><topic>Protein Binding</topic><topic>Quantitative Structure-Activity Relationship</topic><topic>Small Molecule Libraries - chemistry</topic><topic>Small Molecule Libraries - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mehra, Rukmankesh</creatorcontrib><creatorcontrib>Chib, Reena</creatorcontrib><creatorcontrib>Munagala, Gurunadham</creatorcontrib><creatorcontrib>Yempalla, Kushalava Reddy</creatorcontrib><creatorcontrib>Khan, Inshad Ali</creatorcontrib><creatorcontrib>Singh, Parvinder Pal</creatorcontrib><creatorcontrib>Khan, Farrah Gul</creatorcontrib><creatorcontrib>Nargotra, Amit</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular diversity</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mehra, Rukmankesh</au><au>Chib, Reena</au><au>Munagala, Gurunadham</au><au>Yempalla, Kushalava Reddy</au><au>Khan, Inshad Ali</au><au>Singh, Parvinder Pal</au><au>Khan, Farrah Gul</au><au>Nargotra, Amit</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Discovery of new Mycobacterium tuberculosis proteasome inhibitors using a knowledge-based computational screening approach</atitle><jtitle>Molecular diversity</jtitle><addtitle>Mol Divers</addtitle><date>2015-11</date><risdate>2015</risdate><volume>19</volume><issue>4</issue><spage>1003</spage><epage>1019</epage><pages>1003-1019</pages><eissn>1573-501X</eissn><abstract>Mycobacterium tuberculosis bacteria cause deadly infections in patients [Corrected]. The rise of multidrug resistance associated with tuberculosis further makes the situation worse in treating the disease. M. tuberculosis proteasome is necessary for the pathogenesis of the bacterium validated as an anti-tubercular target, thus making it an attractive enzyme for designing Mtb inhibitors. In this study, a computational screening approach was applied to identify new proteasome inhibitor candidates from a library of 50,000 compounds. This chemical library was procured from the ChemBridge (20,000 compounds) and the ChemDiv (30,000 compounds) databases. After a detailed analysis of the computational screening results, 50 in silico hits were retrieved and tested in vitro finding 15 compounds with IC₅₀ values ranging from 35.32 to 64.15 μM on lysate. A structural analysis of these hits revealed that 14 of these compounds probably have non-covalent mode of binding to the target and have not reported for anti-tubercular or anti-proteasome activity. The binding interactions of all the 14 protein-inhibitor complexes were analyzed using molecular docking studies. Further, molecular dynamics simulations of the protein in complex with the two most promising hits were carried out so as to identify the key interactions and validate the structural stability.</abstract><cop>Netherlands</cop><pmid>26232029</pmid><doi>10.1007/s11030-015-9624-0</doi><tpages>17</tpages></addata></record>
fulltext fulltext
identifier EISSN: 1573-501X
ispartof Molecular diversity, 2015-11, Vol.19 (4), p.1003-1019
issn 1573-501X
language eng
recordid cdi_proquest_miscellaneous_1718906971
source Springer Nature
subjects Antitubercular Agents - chemistry
Antitubercular Agents - pharmacology
Computational Biology - methods
High-Throughput Screening Assays - methods
Humans
Molecular Docking Simulation
Molecular Dynamics Simulation
Mycobacterium tuberculosis - drug effects
Mycobacterium tuberculosis - enzymology
Proteasome Inhibitors - chemistry
Proteasome Inhibitors - pharmacology
Protein Binding
Quantitative Structure-Activity Relationship
Small Molecule Libraries - chemistry
Small Molecule Libraries - pharmacology
title Discovery of new Mycobacterium tuberculosis proteasome inhibitors using a knowledge-based computational screening approach
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T21%3A52%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Discovery%20of%20new%20Mycobacterium%20tuberculosis%20proteasome%20inhibitors%20using%20a%20knowledge-based%20computational%20screening%20approach&rft.jtitle=Molecular%20diversity&rft.au=Mehra,%20Rukmankesh&rft.date=2015-11&rft.volume=19&rft.issue=4&rft.spage=1003&rft.epage=1019&rft.pages=1003-1019&rft.eissn=1573-501X&rft_id=info:doi/10.1007/s11030-015-9624-0&rft_dat=%3Cproquest_pubme%3E1718906971%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p126t-fa20f170deda01c0c250bdb970266083069dc215dd674dd9e99407b8bf9176f53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1718906971&rft_id=info:pmid/26232029&rfr_iscdi=true